Trial design strategies for vascular-targeted therapy of patients with ovarian cancer

Clinical Ovarian Cancer

Volumn 2, Issue 1, 2009, Pages 24-30

  Varughese, Mohini A ^a   Ledermann, Jonathan A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Cediranib; ICON6; Multitargeted tyrosine kinase inhibitors; Vascular endothelial growth fact

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BIBF 1120; CARBOPLATIN; CEDIRANIB; CYTOSTATIC AGENT; GEFITINIB; GEMCITABINE; MONOCLONAL ANTIBODY; PACLITAXEL; PAZOPANIB; PLACEBO; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; COST CONTROL; CYTOTOXICITY; DRUG COST; DRUG DESIGN; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PATIENT CODING; SHORT SURVEY; SINGLE DRUG DOSE; TREATMENT RESPONSE;

EID: 77953385597     PISSN: 19414390     EISSN: 19414404     Source Type: Journal    
DOI: 10.3816/COC.2009.n.003     Document Type: Review

References (60)

1. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1-6.
2. Covens A, Carey M, Bryson P, et al. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 2002; 85:71-80.
3. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519-2529
4. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19:1207-1225
5. Algire GH, Chalkley HW, Earle WE, et al. Vascular reactions of normal and malignant tissues in vivo. III. Vascular reactions' of mice to fibroblasts treated in vitro with methylcholanthrene. J Natl Cancer Inst 1950; 11:555-580
6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186
7. Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3:24-40.
8. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82:4-6.
9. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011-1027
10. Gasparini G, Longo R, Toi M, et al. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2005; 2:562-577
11. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-364
12. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219:983-985
13. Ferrara N, Winer J, Burton T, et al. Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. J Clin Invest 1993; 91:160-170
14. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9(suppl 1):2-10. (Pubitemid 38747842)
15. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001; 280:C1358-66.
16. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246:1306-1309
17. Posadas EM, Liel MS, Kwitkowski V, et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007; 109:1323-1330
18. Gordon AN, Finkler N, Edwards RP, et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 2005; 15:785-792
19. Wildiers H, Guetens G, De Boeck G, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003; 88:1979-1986
20. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007; 67:2729-2735
21. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18:4-25.
22. Duncan TJ, Al-Attar A, Rolland P, et al. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res 2008; 14:3030-3035
23. Paley PJ, Staskus KA, Gebhard K, et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997; 80:98-106.
24. Duff SE, Li C, Jeziorska M, et al. Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer 2003; 89:426-430
25. Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001; 2:667-673
26. Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003; 9:5721-5728
27. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
28. Vajkoczy P, Menger MD, Vollmar B, et al. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia 1999; 1:31-41.
29. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841-844
30. Tortora G, Caputo R, Damiano V, et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 2003; 9:1566-1572
31. Brat DJ, Mapstone TB. Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann Intern Med 2003; 138:659-668
32. Yeo EJ, Chun YS, Cho YS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003; 95:516-525
33. Liao D, Corle C, Seagroves TN, et al. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007; 67:563-572
34. Shchors K, Evan G. Tumor angiogenesis: cause or consequence of cancer? Cancer Res 2007; 67:7059-7061
35. O'Reilly MS. The preclinical evaluation of angiogenesis inhibitors. Invest New Drugs 1997; 15:5-13.
36. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-285
37. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79:315-328
38. Yukita A, Asano M, Okamoto T, et al. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo. Anticancer Res 2000; 20(1A):155-160
39. Matulonis UA, Berlin ST, Krasner CN, et al. Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. J Clin Oncol 2008; 26(15 suppl):293s (Abstract 5501).
40. Hirte HW, Vidal L, Fleming GF, et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial. J Clin Oncol 2008; 26(15 suppl):298s (Abstract 5521).
41. ICON6. ICON 6 Trial Development Group. ICON6 Protocol. London. MRC Clinical Trials Unit. 2007;Version 2.2.
42. Biagi JJ, Oza R, Grimshaw R, et al. A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritroneal carcinoma - NCIC CTG IND 185. J Clin Oncol 2008; 26(15 suppl):298s (Abstract 5522).
43. Matei D, Sill MW, DeGeest K, et al. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol 2008; 26(15 suppl):301s (Abstract 5537).
44. Freidlander M, Hancock KC, Benigno B, et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancer: results of a phase II study. Ann Oncol 2008; 19(suppl 8): (Abstract 6630).
45. Harter P, Huober J, Pfisterer P, et al. A phase I dose escalation and pharmacokinetic study of BIBF 1120 in combination with paclitaxel and carboplatin in patients with advanced gynecological malignancies. J Clin Oncol 2007; 25(18 suppl):153s (Abstract 3561).
46. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99:11393-11398
47. Colombo N, Mangili G, Mammoliti S. Aflibercept (VEGF Trap) for advanced epithelial ovarian cancer (EOC) patients (pts) with symptomatic malignant ascites: Preliminary results of a pilot study. J Clin Oncol 2008; 26(15 suppl):635s (Abstract 14598).
48. Tew WP, Colombo I, Ray-Coquard A, et al. VEGF - Trap for patients (pts) with recurrent platinum - resistant epthelial ovarian cancer (EOC): Preliminary results of a randomised, multicenter phase II study. J Clin Oncol 2007; 25(18 suppl):276s (Abstract 5508).
49. Verheul HM, Lolkema MP, Qian DZ, et al. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res 2007; 13:5341-5347
50. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25:5165-5171
51. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25:5180-5186
52. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008; 26:76-82.
53. Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 2007; 105:3-6.
54. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65:4389-4400
55. AstraZeneca Provides Update on RECENTIN Clinical Development Programme. Available at: http://wwwastrazenecacom/pressrelease/5377aspx2008. Accessed: May 10, 2009.
56. Welch S, Hirte H, Schilder RJ, et al. Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: a PMH phase II consortium trial. J Clin Oncol 2006; 24(18 suppl):276s (Abstract 5084).
57. Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008; 26:3709-3714
58. Administration FaD. Innovation or Stagnation. White Paper. Washington, DC: Food and Drug Administration; 2004.
59. Carter SK. Clinical strategy for the development of angiogenesis inhibitors. Oncologist 2000; 5(suppl 1):51-54
60. Parmar MK, Barthel FM, Sydes M, et al. Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst 2008; 100:1204-1214